Inhibition of EZH2 has been proposed as a therapeutic strategy to induce apoptotic cell death in cancers with a frequent gain of function mutation or over-expression of EZH2 such as melanoma, ovarian cancer, and lymphoma [36–38]. Here, EZH2 is linked to ovarian cancer.